Patient characteristics
MPM, TNBC, NSCLC
NON-SMALL CELL LUNG CANCER, TRIPLE NEGATIVE BREAST CANCER, ADENOCARCINOMA, NSCLC, MALIGNANT PLEURAL MESOTHELIOMA, SQUAMOUS CELL CARCINOMA
From February 2013 to April 2015, 18 patients were enrolled who were treated in a dose-escalating fashion (Clinical characteristics of patients treated in the phase I trial.ADC, adenocarcinoma; MPM, malignant pleural mesothelioma; NSCLC, non-small cell lung cancer; PFU, plaque-forming units; SCC, squamous cell carcinoma; TNBC, triple negative breast cancer.